Influence of Pioglitazone for Renal Transplant Function in Diabetics
|Diabetes Mellitus Kidney Transplantation Proteinuria||Drug: pioglitazone||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||Influence of Pioglitazone for Renal Transplant Function in Diabetics - a Double Blind Randomised Placebo Controlled Cross Over Study|
- proteinuria [ Time Frame: 12 weeks ]
- efficacy: filtration fraction, renal nitric oxide bioavailability, insulin resistance, platelet function safety: tolerability, plasma glucose, body weight, edema [ Time Frame: 12 weeks ]
|Study Start Date:||July 2007|
|Study Completion Date:||September 2009|
|Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
About 30 % of kidney transplant recipients will develop diabetes mellitus. This condition is a risk factor for graft dysfunction, graft loss and increased mortality of patients. Inflammatory reactions within the graft and proteinuria are considered as pathogenetic mechanisms.
Recent studies indicated that pioglitazone might have beneficial effects on the urinary protein excretion of type 2 diabetic patients with diabetic nephropathy and was able to reduce systemic inflammation.
This lead to the hypothesis that pioglitazone could improve proteinuria of kidney transplant patients with diabetes.
Comparison: Effects of pioglitazone vs. placebo on proteinuria and renal function of kidney transplant recipients in a cross over study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00507494
|Nephrology, Department of Medicine, university hospital Dresden|
|Dresden, Germany, 01307|
|Principal Investigator:||Peter Gross, MD||Nephrology, Department of Medicine, University hospital Dresden|